Regions of botulinum neurotoxin a light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. the antigenic structure of the active toxin recognized by human antibodies

Immunobiology

Volumn 216, Issue 7, 2011, Pages 782-792

  Atassi, M Zouhair ^a   Dolimbek, Behzod Z ^a   Jankovic, Joseph ^a   Steward, Lance E ^b   Aoki, K Roger ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antibodies; Antigenic sites; Botulinum neurotoxin A; Cervical dystonia; Epitopes; Light chain; Synthetic peptides

Indexed keywords

BOTULINUM TOXIN A; TOXIN ANTIBODY;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CERVICAL DYSTONIA; CLINICAL ARTICLE; HEAVY CHAIN; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNITY; LIGHT CHAIN; PRIORITY JOURNAL; STATIC ELECTRICITY; STRUCTURE ANALYSIS; TEMPERATURE; TOXIN STRUCTURE;

AMINO ACID SEQUENCE; ANTIBODIES, BLOCKING; BOTULINUM TOXINS, TYPE A; DRUG RESISTANCE; EPITOPE MAPPING; HUMANS; IMMUNE SERA; IMMUNODOMINANT EPITOPES; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; TORTICOLLIS;

EID: 79957590025     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.12.009     Document Type: Article

References (56)

1. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., Johnson E.A., Stevens R.C. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 2006, 362:733-742.
2. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Eur. J. Biochem. 1984, 145:1-20.
3. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
4. Atassi M.Z., Dolimbek B.Z. Mapping of the antibody-binding profile on botulinum neurotoxin A HN-domain (residues 449-859) with anti-toxin antibodies from four host species. Antigenic profile of the entire H-chain of botulinum neurotoxin A. Protein J. 2004, 23:39-52.
5. Atassi M.Z., Oshima M. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin. Crit. Rev. Immunol. 1999, 19:219-260.
6. Atassi M.Z., Smith J.A. A proposal for the nomenclature of antigen sites in peptides and proteins. Immunochemistry 1978, 15:609-610.
7. Atassi M.Z., Yoshioka M., Bean M., Bixler B.S. Non-specific peptide size effects in the recognition by site-specific T-cell clones: demonstration with a T site of myoglobin. Biochem. J. 1987, 246:307-312.
8. Atassi M.Z., Dolimbek B.Z., Hayakari M., Middlebrook J.L., Whitney B., Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species. J. Protein Chem. 1996, 15:691-700.
9. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 2008, 45. 3878-3788.
10. Becker-Wegerich P.M., Rauch L., Ruzicka T. Botulinum toxin A: successful decollete rejuvenation. Dermatol. Surg. 2002, 28:168-171.
11. Berglund E.C., Frank A.C., Calteau A., Vinnere Pettersson O., Granberg F., Eriksson A.S., Näslund K., Holmberg M., Lindroos H., Andersson S.G. Run-off replication of host-adaptability genes is associated with gene transfer agents in the genome of mouse-infecting Bartonella grahamii. PLoS Genet. 2009, 5:e1000546.
12. Binder W.J., Brin M.F., Blitzer A., Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis. Mon. 2002, 48:323-335.
13. Bixler G.S., Atassi M.Z. Molecular localization of the full profile of the continuous regions recognized by myoglobin primed T-cells using synthetic overlapping peptides encompassing the entire molecule. Immunol. Commun. 1983, 12:593-603.
14. Bixler G.S., Atassi M.Z. T-cell recognition of myoglobin. Localization of the sites stimulating T-cell proliferative responses by synthetic overlapping peptides encompassing the entire molecule. J. Immunogenet. 1984, 11:339-353.
15. Bixler G.S., Bean M., Atassi M.Z. Site recognition by protein-primed T cells show a non-specific peptide size requirement beyond the essential residues of the site: demonstration by defining an immunodominant T site in myoglobin. Biochem. J. 1986, 240:139-146.
16. Borodic G., Johnson E., Goodnough M., Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996, 46:26-29.
17. Borodic G.E., Acquadro M., Johnson E.A. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Exp. Opin. Invest. Drugs 2001, 10:1531-1544.
18. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432:925-929.
19. Chen S., Barbieri J.T. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem. 2006, 281:10906-10911.
20. Chen S., Kim J.-J.P., Barbieri J.T. Mechanism of substrate recognition by botulinum neurotoxin serotype A. J. Biol. Chem. 2007, 282:9621-9627.
21. Comella C.L., Jankovic J., Daggett S., Mordaunt J., Brin M.F. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type A treatment for cervical dystonia. Neurology 2004, 62:A511. (Abs-P06.141).
22. Danchin A., Fang G., Noria S. The extant core bacterial proteome is an archive of the origin of life. Proteomics 2007, 7:875-889.
23. David C.S., Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. Biol. 1982, 150:97-126.
24. Dickson E.C., Shevky R. Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. II. The effect on the voluntary nervous system. J. Exp. Med. 1923, 37:327-346.
25. Dickson E.C., Shevky R. Botulism studies on the manner in which the toxin of Clostridium botulinum acts upon the body. I. The effect upon the autonomic nervous system. J. Exp. Med. 1923, 37:711-731.
26. Dolimbek B.Z., Jankovic J., Atassi M.Z. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol. Invest. 2002, 31:247-262.
27. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 2005, 34:119-142.
28. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44:1029-1041.
29. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol. Immunol. 2008, 45:910-924.
30. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A. Antigenic structure of the entire toxin. Immunobiology 2010, 10.1016/j.imbio.2010.10.010.
31. Gomis-Rüth F.X., Coll M. Cut and move: protein machinery for DNA processing in bacterial conjugation. Curr. Opin. Struct. Biol. 2006, 16:744-752.
32. Göschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing Abs - therapeutic consequences. Exp. Neurol. 1997, 147:96-102.
33. Gui D., Rossi S., Runfola M., Magalini S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment. Pharm. Therap. 2003, 18:1-16.
34. Hallet B., Sherratt D.J. Transposition and site-specific recombination: adapting DNA cut-and-paste mechanisms to a variety of genetic rearrangements. FEMS Microbiol. Rev. 1997, 21:157-178.
35. Holt R.A., Warren R., Flibotte S., Missirlis P.I., Smailus D.E. Rebuilding microbial genomes. Bioessays 2007, 29:580-590.
36. Humeau Y., Doussau F., Grant N.J., Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82:427-446.
37. Jankovic J. Botulinum toxin: clinical implications of antigenicity immunoresistance. Scientific, Therapeutic Aspects of Botulinum Toxin 2002, 409-415. Lippincott Williams and Wilkins, Philadelphia, PA. M.F. Brin, M. Hallett, J. Jankovic (Eds.).
38. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatr. 2004, 75:951-957.
39. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov. Disord. 2004, 19:S109-S115.
40. Jankovic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
41. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006, 67:2233-2235.
42. Kazim A.L., Atassi M.Z. Haemoglobin binding with haptoglobin. Unequivocal demonstration that the β-chains of human haemoglobin bind to haptoglobin. Biochem. J. 1980, 185:285-287.
43. Kazim A.L., Atassi M.Z. Structurally inherent antigenic sites: localization of the antigenic sites of the α-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 1982, 203:201-208.
44. Kelly B.G., Vespermann A., Bolton D.J. The role of horizontal gene transfer in the evolution of selected foodborne bacterial pathogens. Food Chem. Toxicol. 2009, 47:951-968.
45. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
46. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004, 23:539-552.
47. Mosig G. Recombination and recombination-dependent DNA replication in bacteriophage T4. Annu. Rev. Genet. 1998, 32:379-413.
48. Okuda K.P., Christadoss R., Twining S.S., Atassi M.Z., David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T-lymphocyte proliferative response under H-2 linked Ir gene control. J. Immunol. 1978, 121:866-868.
49. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 1979, 123:182-188.
50. Rossetto O., Schiavo G., Montecucco C., Poulain B., Deloye F., Lozzi L., Shone C.C. SNARE motif and neurotoxons. Nature 1994, 372:415-416.
51. Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Exp. Opin. Pharmacother. 2001, 10:1649-1654.
52. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27:552-558.
53. Twining S.S., David C.S., Atassi M.Z. Genetic control of the immune response to myoglobin. IV. Mouse antibodies in outbred and congenic strains against sperm whale myoglobin recognize the same antigenic sites that are recognized by antibodies raised in other species. Mol. Immunol. 1981, 18:447-450.
54. Washbourne P., Pellizzari R., Baldini G., Wilson M.C., Montecucco C. Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Lett. 1997, 418:1-5.
55. Washbourne P., Bortoletto N., Graham M.E., Wilson M.C., Burgoyne R.D., Montecucco C. Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. J. Neurochem. 1999, 73:2424-2433.
56. Washbourne P., Thompson P.M., Carta M., Costa E.T., Mathews J.R., Lopez-Bendito G., Molnar Z., Becher M.W., Valenzuela C.F., Partridge L.D., Wilson M.C. Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis. Nat. Neurosci. 2002, 5:19-26.